Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...